Chemo-immunotherapy with ibrutinib and indoximod for pediatric brain tumors
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This Phase 1 study tests a combination treatment (ibrutinib plus indoximod along with chemotherapy) for children with brain tumors that have come back or are hard to treat. It may help shrink active tumor or control the disease when standard treatments can’t cure it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your child has a confirmed brain tumor diagnosis (such as ependymoma, medulloblastoma, glioblastoma, or another primary brain/central nervous system cancer) that is growing again or not responding, with no curative treatment option.
- An MRI (with and without contrast dye) must show active tumor right now.
- Your child must be able to swallow pills and take the study medicines by mouth.
- Your child must have “enough strength” for treatment (Lansky/Karnofsky score 50 or higher) and lab results that show kidneys, liver, bone marrow, and blood counts are within required ranges.
- Seizures (if present) must be well controlled on anti-seizure medicine, and you can’t be on other cancer treatments or study medicines not allowed by the protocol while enrolled.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests two drugs, axitinib and etoposide, taken by mouth to treat children and young adults with medulloblastoma or ependymoma that has returned or not responded to standard treatment. The goal is to see if this combination can shrink tumors or slow their growth.
This trial tests a new medicine (RVU120) combined with an existing drug (everolimus) in children whose medulloblastoma (a type of brain tumor) has come back or gotten worse. The goal is to see if this combination can help stop the tumor from growing.
This trial tests whether adding a thyroid hormone (liothyronine) to a standard chemotherapy combination (bevacizumab, irinotecan, temozolomide) can help children and young adults with medulloblastoma that has come back after initial treatment.
This study tests a personalized treatment plan for children and young adults whose medulloblastoma or ependymoma has come back. It aims to guide doctors using new tissue from surgery or biopsy after earlier treatments are fully finished.
This trial tests an experimental oral drug (NLG802) combined with a standard chemotherapy called temozolomide for children and young adults with brain or spinal tumors that have come back or not responded. The goal is to see if this combination is safe and can help fight the tumor.
This trial tests a combination of antiangiogenic drugs (which block blood supply to tumors) for children with certain brain or spinal tumors that have returned or not responded to standard treatment. The goal is to see if this drug combo can shrink or slow the tumor.
Hear when a new Ependymoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.